Get the Stockscreener App
9.08
2.26%
-0.21
Immatics N V stock is traded at $9.08, with a volume of 290.49K.
It is down -2.26% in the last 24 hours and down -9.38% over the past month.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$9.29
Open:
$9.32
24h Volume:
290.49K
Relative Volume:
0.65
Market Cap:
$1.24B
Revenue:
$43.34M
Net Income/Loss:
$-247.99M
P/E Ratio:
-4.6003
EPS:
-1.9738
Net Cash Flow:
$-224.28M
1W Performance:
-5.32%
1M Performance:
-9.38%
6M Performance:
-8.38%
1Y Performance:
+40.78%
1-Day Range:
$9.01
$9.32
1-Week Range:
$9.00
$9.625
52-Week Range:
$5.05
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.08 | 1.24B | 43.34M | -247.99M | -224.28M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMTX|Immatics NV|Price:9.182|Chg%:-0.108 - TradingKey
Immatics NV : Leerink Partners Assumes Covera - Moomoo
Immatics stock trades steady as pipeline and cash position frame biotech outlook - AD HOC NEWS
Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026 - Bitget
Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Investing News Network
MRNA Advances Cancer Pipeline With New Immunotherapy Study - TradingView
Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative
Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage R&D InvestmentEarnings Growth Analysis - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline ProgressPre-Announcement Alert - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Biotech Navigates Clinical Pipeline CostsAnalyst Drop Coverage - dars.gov.et
(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immatics (IMTX) Slides 3.11% Amid Biotech Sector Pressure – Support at $9.17 in FocusRounding Bottom - dars.gov.et
Immatics (IMTX) Holds Near Support as Slight Dip Signals Cautious TradingGap Down Bounce Plays - dars.gov.et
Immatics stock holds attention. The focus shifts to its pipeline. - Ad Hoc News
Immatics (IMTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech StockRevenue Beat Analysis - Bölüm Sonu Canavarı
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Development Costs WeighQuarterly Earnings - dars.gov.et
Immatics N.V. Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage InvestmentEarnings Sentiment Score - dars.gov.et
Responsive Playbooks and the IMTX Inflection - Stock Traders Daily
Immatics N.V. Actuals & Estimates (NASDAQ:IMTX) - TradingView
Immatics (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentRevenue Guidance Range - dars.gov.et
Enterprise value to revenue forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Price to book forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – MUN:4A3 - TradingView
IMTX Forecast — Price Target — Prediction for 2027 - TradingView
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Higher R&D Investment; Pipeline Progress Continues - dars.gov.et
Immatics N.V. Actuals & Estimates (TRADEGATE:4A3) - TradingView
Immatics N.V. Actuals & Estimates (FWB:4A3) - TradingView
Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV (IMTX) Institutional Confidence - TradingKey
Understanding the Setup: (IMTX) and Scalable Risk - Stock Traders Daily
Immatics Shareholders Approve All Proposals at June 18, 2026 AGM - The Globe and Mail
Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award - Stock Titan
Immatics (IMTX) awards director Alise Reicin 48,000 stock options - Stock Titan
Immatics (IMTX) director receives grant of 48,000 stock options at $9.09 - Stock Titan
Immatics (IMTX) director receives 48,000 stock options vesting in 2026 - Stock Titan
Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares - Stock Titan
Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09 - Stock Titan
Immatics (IMTX) director Heather Mason receives 48,000 stock options at $9.09 strike - Stock Titan
48,000 Immatics (IMTX) options tied to board role granted - Stock Titan
Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike - Stock Titan
Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout - Stock Titan
Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics NV (IMTXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics NV (IMTXW) Institutional Confidence - TradingKey
Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immatics NV (IMTXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):